The Immediate Effects of Vagus Nerve Stimulation in Intractable Epilepsy: An Intra-operative Electrocorticographic Analysis

Rintaro YOKOYAMA,1 Yukinori AKIYAMA,1 Rei ENATSU,1 Hime SUZUKI,1 Yuto SUZUKI,1 Aya KANNO,1 Satoko OCHI,1 and Nobuhiro MIKUNI1

1Department of Neurosurgery, Sapporo Medical University, Sapporo, Hokkaido, Japan

Abstract

The purpose of this study was to investigate whether and how vagus nerve stimulation (VNS) reduces the epileptogenic activity in the bilateral cerebral cortex in patients with intractable epilepsy. We analyzed the electrocorticograms (ECoGs) of five patients who underwent callosotomy due to intracerebral epilepsy even after VNS implantation. We recorded ECoGs and analyzed power spectrum in both VNS OFF and ON phases. We counted the number of spikes and electrodes with epileptic spikes, distinguishing unilaterally and bilaterally hemispherically spread spikes as synchronously of the epileptic spikes in both VNS OFF and ON phases. There were 24.80 ± 35.55 and 7.20 ± 9.93 unilaterally spread spikes in the VNS OFF and ON phases, respectively (P = 0.157), and 35.8 ± 29.21 and 10.6 ± 13.50 bilaterally spread spikes in the VNS OFF and ON phases, respectively (P = 0.027). The number of electrodes with unilaterally and bilaterally spread spikes in the VNS OFF and ON phases was 3.84 ± 2.13 and 3.59 ± 1.82 (P = 0.415), and 8.20 ± 3.56 and 6.89 ± 2.89 (P = 0.026), respectively. The ECoG background power spectra recordings in the VNS OFF and ON phases were also analyzed. The spectral power tended to be greater in the high-frequency band at VNS ON phase than OFF phase. This study showed the reduction of epileptogenic spikes and spread areas of the spikes by VNS as immediate effects, electrophysiologically.

Key words: vagus nerve stimulation, electrocorticogram analysis, immediate effect

Introduction

Vagus nerve stimulation (VNS) is a palliative therapy for drug-resistant, intractable epilepsy that restrains an epileptic seizure by providing intermittent electric stimulations to the cervical vagus nerve. The clinical application of VNS was started based on the fundamental researches in an animal model in the United States in 1988, and health insurance coverage for VNS was applicable in Japan in 2010.1,2 Several large clinical trials have demonstrated the results of VNS; thus, there is no room for doubt in terms of its effectiveness in the treatment of intractable epilepsy.3,4 In addition, improvement of the cognitive function and emotional disorder has been known as a parallel effect associated with the restraint of epileptic seizures using VNS.5 VNS has been used in clinical practice for the treatment of refractory depression since it was approved by the Food and Drug Administration (FDA) in the United States in 2005. Furthermore, it has been suggested as a treatment option for chronic migraine6,7) and the aftereffects of cerebral infarction due to its anti-inflammatory action; therefore, VNS should be applied in the treatment of more diseases in the future.8,9) The responder ratio of the VNS treatment is 25%, 37%, and 50% at 3 months, 1 year, and 5 years during a treatment period, respectively.10,11) Although the mechanisms of the VNS treatment are still unclear, it has been suggested that its long-term effect is due to the modification of the extensive cerebrocortical activation by the deep brain nuclei, such as the thalamus, through the neurotransmitters, including the noradrenaline system.12–14) However, few studies have been performed to analyze the immediate effect of VNS on the brain. It has been suggested in a prior study that the effect of VNS was associated with a direct or indirect influence on the electrophysiological modulation and/or the broad spread of the epileptogenic activity, from the nuclei of the solitary tract to the bilateral cortices.
in the acute phase.\textsuperscript{15,16} In this study, we analyzed and compared the electrocorticogram changes before and after VNS stimulation during operations.

**Materials and Methods**

**Patient population**

The study subjects were five patients with intractable epilepsy who underwent an additional craniotomy (callosotomy) as a multistage-palliative treatment in our department between 2014 and 2018 because the effect of the preceded VNS therapy was insufficient or their satisfaction was poor. There were three males and two females, with an age range between 14 and 39 years (mean 26.2). These five patients were all poor-responder of VNS therapy. The patients’ characteristics are summarized in Table 1. The mean period between the VNS surgery and callosotomy was 35 months.

This study was approved by the Ethical Committee of Sapporo Medical University Graduate School of Medicine, and written informed consent was obtained from all patients. When children were involved in this study, the permission of their parents was obtained.

**Electrocorticogram recordings**

All patients were administered general anesthesia by anesthesiologists, with the end-tidal sevoflurane concentration maintained at 2% during the electrocorticogram (ECoG) recording. The ECoG data were recorded using an MEE-1232 machine (Nihon Kohden, Tokyo, Japan), using a preamplifier bandwidth of 0.5–100 Hz and a sampling rate of 500 Hz. Two \(1 \times 6\) or \(2 \times 8\) subdural electrodes grids (10 mm intercontact distance, each contact distant with 3 mm diameter (Unique Medical, Tokyo, Japan)) were placed on the bilateral frontal cortices intraoperatively (Fig. 1); the reference electrode was placed on the earlobe, and the earth electrode was placed on the nasion. To precisely differentiate the VNS OFF and ON phases, an electrocardiogram was recorded at the same time to capture the stimulation artifact. During the VNS ON phases, the stimulation was associated with a 30 Hz activity detected on the electrocardiogram (Fig. 2).

The ECoG recordings consisted of discontinuous 180 s added consecutive 60 s three times each in the VNS ON and OFF phases before the start of the corpus callosotomy. A normal mode of VNS was turned off before the operations, and only a magnet mode was used for the recordings in the VNS ON phases, of which duration was 60 s. In order to avoid the influence of the VNS, the ECoG recordings were performed at least 60 s apart from the stimulation.

| Table 1: Patients’ characteristics | Case | Age, gender | Seizure type | Epilepsy type | Epilepsy classification | VNS duration | VNS parameter | VNS parameter | Magnet mode parameters (intensity, pulse width) |
|-----------------------------------|------|-------------|--------------|---------------|-------------------------|--------------|---------------|---------------|-----------------------------------------------|
| 1                                 | 17 years, Male | GA, GM, GTC | LCS          | LGS           | Class III               | 29 months   | 2.0 mA, 500 μs | 2.25 mA, 750 μs | 2.25 mA, 750 μs, 60 s                          |
| 2                                 | 14 years, Female | GA, GTC | LCS          | LGS           | Class III               | 33 months   | 2.0 mA, 500 μs | 2.25 mA, 750 μs | 2.5 mA, 500 μs, 60 s                          |
| 3                                 | 33 years, Male | FIA, GA, FNE | LCS | Cortical dysplasia | Class II | 26 months | 2.25 mA, 500 μs | 2.5 mA, 750 μs | 2.25 mA, 750 μs, 60 s                          |
| 4                                 | 28 years, Male | FIA, GA, GTC | LCS | Cortical dysplasia | Class II | 23 months | 2.0 mA, 750 μs | 2.0 mA, 750 μs | 1.875 mA, 500 μs, 60 s                          |
| 5                                 | 39 years, Male | FIA, GA, GTC | Unknown | Unknown | Class III | 62 months | 1.625 mA, 500 μs | 1.875 mA, 500 μs | 1.875 mA, 500 μs, 60 s                          |

GA: generalized, atomic, CM: generalized tonic-clonic, GTC: generalized tonic-clonic, FIA: focal impaired awareness, PTE: psychogenic non-epileptic, LCS: Lennox-Gastaut syndrome, CBZ: clobazam, CZP: clonazepam, ESM: ethosuximide, LEV: levetiracetam, PHT: phenytoin, PB: phenobarbital, TPM: Topiramate, VPA: valproic acid, ZNS: zonisamide.
The Immediate Effects of Vagus Nerve Stimulation

Fig. 1  (A) An intraoperative factual image of case 4. Two 2 × 8 subdural electrodes grids were placed on the bilateral frontal cortices. (B) A fusion image of 3D computed tomography and schematic electrodes grids.

Fig. 2  An example of ECoG recordings of the bilateral hemispheres in case 3 during the vagus nerve stimulation (VNS) ON and OFF phases. The artifact of VNS stimulation is recorded on the ECG during the VNS ON phases. The unilateral spikes were defined as discharges spreading unilaterally hemispherically (black arrowhead), and also the bilateral spikes were defined as discharges spreading bilaterally hemispherically with synchronousness (white arrowhead). ECoG: electrocorticogram.
during the VNS OFF phases. In each patient, the usual VNS parameters were recorded (Table 1).

**ECoG analysis**

The records were reviewed and annotated by two neurosurgeons, board-certified members of the Japanese Epilepsy Society, who were blinded to the VNS ON and OFF phases. We analyzed the spikes that they both matched and excluded the ones with an amplitude of <400 μV. We counted a spike and wave complex as one spike.

We analyzed the number of spikes, the maximum amplitude of the spikes, and the number of electrodes where the spikes were shown. The power spectrum was then analyzed and compared between the VNS OFF and ON phases. The power spectrum was calculated by a fast Fourier transform range 1–60 Hz using MATLAB (Mathworks, Natick, MA, USA), and the number of points in the fast Fourier transform was configured to 500. We used all the electrodes of each patient for this analysis except ones containing artifacts or noise obviously caused by electronic devices and motion.

**Statistical analysis**

The data are expressed as means ± standard deviations. We used the Wilcoxon paired samples test to identify the group differences. Repeated measure analysis of variance was used to analyze the spectral power in each frequency.

All statistical analyses were conducted using the SPSS software package (version 12; SPSS Inc., Chicago, IL, USA). P < 0.05 was considered to indicate statistical significance.

**Results**

**Patients’ characteristics**

We observed five consecutive patients with intractable epilepsy despite multiple anti-epileptic drugs and even VNS implantation, who were scheduled to undergo callosotomy in our institution. The subjects’ age ranged between 14 and 39 years (mean 26.2).

All patients were diagnosed with a generalized onset as seizure type and generalized epilepsy as epilepsy type, according to the International League Against Epilepsy (ILAE) classification of the epilepsies 2017.17,18 The seizure types in all patients are described in Table 1, as follows: generalized atonic (GA), generalized myoclonic (GM), and generalized tonic–clonic (GTC) in case 1; GA and GTC in case 2; focal impaired awareness (FIA), GA, and psychogenic non-epileptic in case 3; and FIA, GA, and GTC in cases 4 and 5. The epilepsy types were West syndrome (WS) and Lennox–Gastaut syndrome (LGS) in case 1, LGS in cases 2–4, and unknown in case 5; McHugh Classification class III in cases 1, 2, and 5, and class II in cases 3 and 4 (Table 1).

In all cases, except for case 1, the frequency of the seizure attacks (FSA) had dramatically decreased soon after VNS implantation; however, after 1–2 years, the FSA gradually increased and the symptoms deteriorated. In case 1, although the complex seizure attacks had decreased after the VNS implantation, the drop attack had not decreased. Accordingly, the patients were scheduled to undergo callosotomy 23–63 months after the VNS implantation.

**ECoGs recordings**

During the callosotomy, we evaluated and compared the ECoGs between the VNS ON and OFF phases using subdural electrodes on both sides of the brain. The mean values of each of the following parameters VNS OFF phases versus ON phases, respectively. We counted the number of spikes, distinguishing the unilaterally hemispherically spread and the bilaterally hemispherically spread spikes as synchronousness of the epileptic spikes in both the VNS ON and OFF phases.

The number of unilaterally spread spikes in the VNS OFF and ON phases was 2–78 (mean 24.80 ± 35.55) and 0–23 (mean 7.20 ± 9.93), respectively; the difference was not statistically significant (P = 0.157). In contrast, the number of bilaterally spread spikes in the VNS OFF and ON phases was 5–83 (mean 35.8 ± 29.21) and 1–34 (mean 10.6 ± 13.50), respectively; the difference was statistically significant (P = 0.027).

The number of electrodes with unilaterally spread spikes in the VNS OFF and ON phases was 1–13 (mean 3.84 ± 2.13) and 1–8 (mean 3.59 ± 1.82), respectively; the difference was not statistically significant (P = 0.415). In contrast, the number of electrodes with bilaterally spread spikes was 2–18 (mean 8.20 ± 3.56) and 2–15 (mean 6.89 ± 2.89) in the VNS OFF and ON phases, respectively; the difference was statistically significant (P = 0.026).

The maximum amplitude (mV) of the unilaterally spread spikes in the VNS OFF and ON phases was 0.41–1.72 (mean 1.03 ± 0.27) and 0.41–1.58 (mean 1.06 ± 0.24), respectively; the difference was not statistically significant (P = 0.391). The maximum amplitude (mV) of the bilaterally spread spikes in the VNS OFF and ON phases was 0.42–1.88 (mean 1.04 ± 0.33) and 0.42–1.58 (mean 0.99 ± 0.30), respectively; the difference was also not statistically significant (P = 0.438). A significant reduction in both the number of spikes and electrodes were shown in the VNS ON phases. This effect was more pronounced for the bilaterally than for the unilaterally spread spikes (Table 2).
The Immediate Effects of Vagus Nerve Stimulation

The ECoG background power spectra recordings were also analyzed in the VNS OFF and ON phases. We classified the frequency bands as $\delta$: 1–3 Hz, $\theta$: 4–7 Hz, $\alpha$: 8–13 Hz, $\beta$: 14–30 Hz, and $\gamma$: more than 31 Hz. The mean values of each spectral band in the VNS OFF and ON phases were as follows: $\delta$, 0.13 ± 0.45 and 0.12 ± 0.44 ($P = 0.002$); $\theta$, 0.58 ± 0.20 and 0.57 ± 0.17 ($P = 0.920$); $\alpha$, 0.41 ± 0.25 and 0.43 ± 0.21 ($P = 0.068$); $\beta$, 0.066 ± 0.0702 and 0.078 ± 0.075 ($P < 0.001$); and $\gamma$, 0.0041 ± 0.0053 and 0.0059 ± 0.0078, respectively ($P < 0.001$) (Fig. 3). The spectral power tended to be greater in the high-frequency bands and in the VNS ON phases. VNS may induce an increase of the spectral power in the high-frequency bands, particularly in the $\beta$ and $\gamma$ bands.

**Discussion**

Vagus nerve stimulation is a palliative therapy for refractory epilepsy that restrains an epileptic seizure by providing intermittent electric stimulations to the cervical vagus nerve. The aim of this study was to evaluate the effectiveness of VNS for suppression of the epileptic seizure using electrocorticography with subdural electrodes. Previous studies have analyzed the effect of VNS using electroencephalography (EEG) on the scalp, and demonstrated a decrease in the epileptic spikes and de-synchronousness as a long-term effect of VNS.\(^{19–21}\)

As stated above, the mechanisms of the epileptic seizure suppression with VNS is unclear. Various
possibilities have been suggested, such as the change in the neurotransmitters’ concentration, expression of a new protein, and change in the local brain blood flow. Most of the previous studies demonstrated the VNS long-term effects using the trans-scalp EEG recording. Bartolomei et al. reported an evaluation with an intracranial electrode for the first time using stereotactic EEG (SEEG), and mentioned the possibility that the functional connectivity between the corticocortical neurons may be changed by VNS. Although subdural electrocorticography has many advantages including the sensitivity, preciseness, and spatial resolution, there are also some disadvantages compared with the transcranial electroencephalography, such as invasiveness and area coverage. Some recent studies have reported on a non-invasive stimulation of other cranial nerves, such as trigeminal nerve stimulation and that percutaneous VNS could have effects similar to those of the conventional VNS.

In this study, interestingly, the VNS effects of decreased epileptic spikes and spread area were more pronounced in the bilaterally spread spikes than in the unilaterally spread spikes. Previous studies have suggested that patients with generalized seizure subtypes improved better in response to VNS than those with focal seizures. Moreover, the seizure-free rate in patients undergoing VNS therapy was also described to be higher in the patients with primarily generalized seizures. Although it is not fully understood why the VNS effects are more pronounced in patients with generalized than in those with focal seizures, our data might provide one explanation for it. Some authors showed that VNS may induce a decrease in the synchronization of the epileptic spikes. This suggests that our findings can support the results of the past studies.

The spectral power tended to be greater in the high-frequency bands in the VNS ON phases than in the VNS OFF phases. This power spectral finding suggests that the frontal cortex cells were electro-neurophysiologically affected by VNS. Gamma activity has previously been found to be increased in patients with epilepsy.

According to past reports, the action potential caused by the electrical stimulation of the vagus nerve is conducted afferently to the cerebral cortex through the nuclei of the solitary tract of the brainstem, suppressing the corticocortical electric activity in both sides through the thalamus, limbic system, putamen, and other regions. Notably, in this study, we found a reduction of the epileptogenic spikes in the inter-ictal phases in both hemispheres as an immediate effect of VNS using the subdural electrodes. Because the VNS effect in this study occurred soon after its activation as an immediate effect, the electrophysiological mechanism may have directly or indirectly affected the cerebral cortex, which was supported with the ECoGs.

The limitations of this study are as follows. First, all subjects were clinically non- or poor-responders to VNS because of the study design. The mechanism of the VNS effect may be further elucidated by evaluating patients who respond to VNS using an ECoG analysis. Second, the electrocorticography evaluation could be performed only for a short period and in a limited area. An evaluation of a broader area of the cortex can provide a more precise analysis in terms of the epileptic seizures’ spread in the brain. Finally, in this study, we could compare the profiles of the epileptogenic spikes in both the VNS OFF and ON phases only during the inter-ictal phases. It is much more important to evaluate the spikes in the ictal phases; however, that was impossible to do during the craniotomy surgery.

We would like to emphasize that the results of this study proved the hypothesis that VNS adjusts, modifies, and controls an abnormal epilepsy-related network.

**Conclusion**

In this study, we found that VNS induced a reduction in the epileptogenic spikes and the spread areas of the spikes in the inter-ictal period as immediate effects, which suggested that VNS can restrain the neurophysiologic activity of an abnormal epilepsy-related network in the cerebral cortex through the nuclei of the solitary tract even in non- or poor-responding patients. Nonetheless, further investigation is necessary.

**Conflicts of Interest Disclosure**

The authors have no competing interests to disclosure.

**References**

1. Kawai K: Vagus nerve stimulation therapy for epilepsy. *Brain Nerve* 63: 331–346, 2011 (Japanese)
2. Kawai K, Tanaka T, Baba H, et al.: Outcome of vagus nerve stimulation for drug-resistant epilepsy: the first three years of a prospective Japanese registry. *Epileptic Disord* 19: 327–338, 2017
3. A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. The vagus nerve stimulation study group. *Neurology* 45: 224–230, 1995
4. Handforth A, DeGiorgio CM, Schachter SC, et al.: Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. *Neurology* 51: 48–55, 1998
The Immediate Effects of Vagus Nerve Stimulation

5) Rush AJ, George MS, Sackeim HA, et al.: Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. *Biol Psychiatry* 47: 276–286, 2000

6) Silberstein SD, Calhoun AH, Lipton RB, et al.: Chronic migraine headache prevention with noninvasive vagus nerve stimulation: the EVENT study. *Neurology* 87: 529–538, 2016

7) Straube A, Ellrich J, Eren O, Blum B, Ruscheweyh R: Treatment of chronic migraine with transcutaneous stimulation of the auricular branch of the vagal nerve (auricular t-VNS): a randomized, monocentric clinical trial. *J Headache Pain* 16: 543, 2015

8) Bonaz B, Sinniger V, Pellissier S: Vagus nerve stimulation: a new promising therapeutic tool in inflammatory bowel disease. *J Intern Med* 282: 46–63, 2017

9) Browning KN, Verheijden S, Boeckxstaens GE: The vagus nerve in appetite regulation, mood, and intestinal inflammation. *Gastroenterology* 152: 730–744, 2017

10) Elliott RE, Morsi A, Tanweer O, et al.: Efficacy of vagus nerve stimulation over time: review of 65 consecutive patients with treatment-resistant epilepsy treated with VNS > 10 years. *Epilepsy Behav* 20: 478–483, 2011

11) Morris GL 3rd, Mueller WM: Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01-E05. *Neurology* 53: 1731–1735, 1999

12) Manta S, Dong J, Debonnel G, Blier P: Enhancement of the function of rat serotonin and norepinephrine neurons by sustained vagus nerve stimulation. *J Psychiatry Neurosci* 34: 272–280, 2009

13) Marrosu F, Serra A, Maleci A, Puligheddu M, Biggio G, Piga M: Correlation between GABA(A) receptor density and vagus nerve stimulation in individuals with drug-resistant partial epilepsy. *Epilepsy Res* 55: 59–70, 2003

14) Roosevelt RW, Smith DC, Clough RW, Jensen RA, Browning RA: Increased extracellular concentrations of norepinephrine in cortex and hippocampus following vagus nerve stimulation in the rat. *Brain Res* 1119: 124–132, 2006

15) Morris GL 3rd: A retrospective analysis of the effects of magnet-activated stimulation in conjunction with vagus nerve stimulation therapy. *Epilepsy Behav* 4: 740–745, 2003

16) Fisher RS, Eggleston KS, Wright CW: Vagus nerve stimulation magnet activation for seizures: a critical review. *Acta Neurol Scand* 131: 1–8, 2015

17) Fisher RS, Cross JH, French JA, et al.: Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. *Epilepsia* 58: 522–530, 2017

18) Scheffer IE, Berkovic S, Capovilla G, et al.: ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. *Epilepsia* 58: 512–521, 2017

19) Bodin C, Aubert S, Daquin G, et al.: Responders to vagus nerve stimulation (VNS) in refractory epilepsy have reduced interictal cortical synchronicity on scalp EEG. *Epilepsy Res* 113: 98–103, 2015

20) Halldbök T, Lundgren J, Blennow G, Strömblad LG, Rosén I: Long term effects on epileptiform activity with vagus nerve stimulation in children. *Seizure* 14: 527–533, 2005

21) Koo B: EEG changes with vagus nerve stimulation. *J Clin Neurophysiol* 18: 434–441, 2001

22) Ben-Menachem E, Hamberger A, Hedner T, et al.: Effects of vagus nerve stimulation on amino acids and other metabolites in the CSF of patients with partial seizures. *Epilepsy Res* 20: 221–227, 1995

23) Hammond EJ, Uthman BM, Wilder BJ, et al.: Neurochemical effects of vagus nerve stimulation in humans. *Brain Res* 583: 300–303, 1992

24) Hassert DL, Miyashita T, Williams CL: The effects of peripheral vagal nerve stimulation at a memory-modulating intensity on norepinephrine output in the basolateral amygdala. *Behav Neurosci* 118: 79–88, 2004

25) Naritoku DK, Terry WJ, Helfert RH: Regional induction of fos immunoreactivity in the brain by anticonvulsant stimulation of the vagus nerve. *Epilepsy Res* 22: 53–62, 1995

26) Dedeurwaerdere S, Vonck K, Van Hese P, Wadman W, Boon P: The acute and chronic effect of vagus nerve stimulation in genetic absence epilepsy rats from Strasbourg (GAERS). *Epilepsia* 46: 94–97, 2005

27) Garnett ES, Nahmias C, Scheffel A, Firnau G, Upton AR: Regional cerebral blood flow in man manipulated by direct vagal stimulation. *Pacing Clin Electrophysiol* 15: 1579–1580, 1992

28) Henry TR, Bakay RA, Ponnell PB, Epstein CM, Votaw JR: Brain blood-flow alterations induced by therapeutic vagus nerve stimulation in partial epilepsy: II. prolonged effects at high and low levels of stimulation. *Epilepsia* 45: 1064–1070, 2004

29) Vonck K, De Herdt V, Bosman T, Dedeurwaerdere S, Van Laere K, Boon P: Thalamic and limbic involvement in the mechanism of action of vagus nerve stimulation, a SPECT study. *Seizure* 17: 699–706, 2008

30) Bartolomei F, Bonini F, Vidal E, et al.: How does vagal nerve stimulation (VNS) change EEG brain functional connectivity? *Epilepsy Res* 126: 141–146, 2016

31) Enatsu R, Mikuni N: Invasive evaluations for epilepsy surgery: a review of the literature. *Neurol Med Chir (Tokyo)* 56: 221–227, 2016

32) Tamada T, Enatsu R, Suzuki Y, et al.: Psychogenic pseudo-responses in an electrical cortical stimulation. *Neural Med Chir (Tokyo)* 59: 287–290, 2019

33) DeGiorgio CM, Krahl SE: Neurostimulation for drug-resistant epilepsy. *Continuum (Minneap Minn)* 19: 743–755, 2013

34) Frangos E, Ellrich J, Komisaruk BR: Non-invasive access to the vagus nerve central projections via electrical stimulation of the external ear: fMRI evidence in humans. *Brain Stimul* 8: 624–636, 2015

35) Stefan H, Kreiselmeyer G, Kerling F, et al.: Transcutaneous vagus nerve stimulation (t-VNS) in
pharmacoresistant epilepsies: a proof of concept trial. *Epilepsia* 53: e115–e118, 2012

36) Englot DJ, Chang EF, Auguste KI: Vagus nerve stimulation for epilepsy: a meta-analysis of efficacy and predictors of response. *J Neurosurg* 115: 1248–1255, 2011

37) Englot DJ, Han SJ, Rolston JD, et al.: Epilepsy surgery failure in children: a quantitative and qualitative analysis. *J Neurosurg Pediatr* 14: 386–395, 2014

38) Englot DJ, Raygor KP, Molinaro AM, et al.: Factors associated with failed focal neocortical epilepsy surgery. *Neurosurgery* 75: 648–645; discussion 655; quiz 656, 2014

39) Englot DJ, Rolston JD, Wang DD, Hassnain KH, Gordon CM, Chang EF: Efficacy of vagus nerve stimulation in posttraumatic versus nontraumatic epilepsy. *J Neurosurg* 117: 970–977, 2012

40) Fraschini M, Puligheddu M, Demuru M, et al.: VNS induced desynchronization in gamma bands correlates with positive clinical outcome in temporal lobe pharmacoresistant epilepsy. *Neurosci Lett* 536: 14–18, 2013

41) Jaseja H: EEG-desynchronization as the major mechanism of anti-epileptic action of vagal nerve stimulation in patients with intractable seizures: clinical neurophysiological evidence. *Med Hypotheses* 74: 855–856, 2010

42) Marrosu F, Santoni F, Puligheddu M, et al.: Increase in 20-50 Hz (gamma frequencies) power spectrum and synchronization after chronic vagal nerve stimulation. *Clin Neurophysiol* 116: 2026–2036, 2005

43) Mackenzie L, Medvedev A, Hiscock JJ, Pope KJ, Willoughby JO: Picrotoxin-induced generalised convulsive seizure in rat: changes in regional distribution and frequency of the power of electroencephalogram rhythms. *Clin Neurophysiol* 113: 586–596, 2002

44) Willoughby JO, Fitzgibbon SP, Pope KJ, et al.: Persistent abnormality detected in the non-ictal electroencephalogram in primary generalised epilepsy. *J Neurol Neurosurg Psychiatry* 74: 51–55, 2003

45) Bagary M: Epilepsy, consciousness and neurostimulation. *Behav Neurol* 24: 75–81, 2011

46) Fanselow EE: Central mechanisms of cranial nerve stimulation for epilepsy. *Surg Neurol Int* 3: S247–S254, 2012

Address reprint requests to: Nobuhiro Mikuni, MD, PhD, Department of Neurosurgery, Sapporo Medical University, South 1, West 16, Chuo-ku, Sapporo, Hokkaido 060-8543, Japan.

e-mail: mikunin@sapmed.ac.jp